EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance

Haojie Jiang, Shunhui Cai, Xiaojun Zhang, Shijie Chen, Chunyan Yue, Wu Yin, Yiqiao Hu

Drugs in R&D · 2026-03 · 26 (1) · 101-115

DOI: 10.1007/s40268-025-00534-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs in R&D, online erschienen am 03.04.2026. Verfasst von Haojie Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pharmaceutical Biotechnology, Medical School & School of Life Sciences, Nanjing University, SLiS Building, Xianlin Campus, No…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Erlotinib Hydrochloride, Hypoxia-Inducible Factor 1, alpha Subunit, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Collaborative Innovation Project of Yangtze River Delta Science and Technology Community, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality. While EGFR tyrosine kinase inhibitors (EGFR-TKIs) have improved survival, acquired resistance mediated by tumor hypoxia and HIF-1α stabilization often leads to treatment failure. This study investigated the regulatory role of HIF-1α in NSCLC drug resistance and evaluated a combined therapeutic strategy to overcome EGFR-TKI resistance. METHODS: HIF-1α expression and downstream targets were assessed in H1975 and A549 cell lines using RT-qPCR and Western blot. Functional assays, including cell proliferation, apoptosis, invasion, lactate production, and ROS measurements, were performed following HIF-1α siRNA transfection and/or erlotinib treatment. Bioinformatics analyses of public datasets evaluated clinical relevance and pathway enrichment. RESULTS: HIF-1α knockdown inhibited glycolysis, reduced lactate production, and alleviated hypoxia-induced oxidative stress. Combined treatment with HIF-1α siRNA and erlotinib synergistically suppressed cell proliferation, induced apoptosis, and inhibited invasion more effectively than single-agent treatments. Mechanistically, EGFR signaling positively regulated HIF-1α stability via the PI3K/AKT and MEK/ERK pathways. Bioinformatics confirmed that high HIF-1α expression correlates with poor prognosis in NSCLC patients. CONCLUSION: Targeting HIF-1α disrupts metabolic reprogramming and hypoxia adaptation, thereby enhancing erlotinib efficacy. This combined approach highlights the therapeutic potential of HIF-1α inhibition as a novel strategy to overcome EGFR-TKI resistance in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungErlotinib HydrochlorideHypoxia-Inducible Factor 1, alpha SubunitDrug Resistance, NeoplasmLung NeoplasmsRNA, Small InterferingHumansCell ProliferationApoptosisCell Line, TumorProtein Kinase InhibitorsErbB ReceptorsSignal TransductionA549 Cells

Substanzen

Erlotinib HydrochlorideHypoxia-Inducible Factor 1, alpha SubunitRNA, Small InterferingHIF1A protein, humanProtein Kinase InhibitorsErbB Receptors

Autor:innen und Institutionen

  • State Key Laboratory of Pharmaceutical Biotechnology, Medical School & School of Life Sciences, Nanjing University, SLiS Building, Xianlin Campus, No. 163 of Xianlin Avenue, Qixia District, Nanjing, 210093, China.
  • Jiangsu Key Laboratory for Nano Technology, Nanjing University, Nanjing, China.
  • Institute of Drug R&D, School of Life Science, Nanjing University, Nanjing, China.
  • State Key Laboratory of Pharmaceutical Biotechnology, Medical School & School of Life Sciences, Nanjing University, SLiS Building, Xianlin Campus, No. 163 of Xianlin Avenue, Qixia District, Nanjing, 210093, China. yuech…
  • Jiangsu Key Laboratory for Nano Technology, Nanjing University, Nanjing, China. yuechunyan@nju.edu.cn.
  • Institute of Drug R&D, School of Life Science, Nanjing University, Nanjing, China. yuechunyan@nju.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Collaborative Innovation Project of Yangtze River Delta Science and Technology Community
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Jiang, H., Cai, S., Zhang, X., Chen, S., Yue, C., Yin, W., & Hu, Y. (2026). HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance. Drugs in R&D, 26(1), 101-115. https://doi.org/10.1007/s40268-025-00534-5

Vancouver

Jiang H, Cai S, Zhang X, Chen S, Yue C, Yin W, et al. HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance. Drugs in R&D. 2026;26(1):101-115. doi:10.1007/s40268-025-00534-5

BibTeX
@article{Jiang2026,
  author = {Jiang, Haojie and Cai, Shunhui and Zhang, Xiaojun and Chen, Shijie and Yue, Chunyan and Yin, Wu and Hu, Yiqiao},
  title = {HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance},
  journal = {Drugs in R&D},
  year = {2026},
  volume = {26},
  number = {1},
  pages = {101--115},
  doi = {10.1007/s40268-025-00534-5}
}
Kostenlos starten →